Baxter International Inc
BAX:NYSE
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
| 73.02 | 0.21 0.29% | 2.68% | 2,842,486 | 2.5M |
Market data is delayed by at least 20 minutes.
Latest News Headlines for Baxter International Inc
Baxter Declares Quarterly Dividend
DEERFIELD, Ill.--(BUSINESS WIRE)--July 23, 2013--
The Board of Directors of Baxter International Inc. (NYSE:BAX) today declared a quarterly dividend of $0.49 per Baxter common share. The dividend is payable on October 1, 2013 to shareholders of record as of September 6, 2013.
Increased Demand, Fast Track Designations, and Strong Sales Boost Revenue Growth - Research Report on Alexion, Baxter International, Align Technology, Transition, and OPKO
Editor Note: For more information about this release, please scroll to bottom
NEW YORK, July 23, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Baxter International Inc. (NYSE: BAX), Align Technology, Inc. (NASDAQ: ALGN), Transition Therapeutics Inc. (NASDAQ: TTHI), and OPKO Health Inc. (NYSE: OPK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
European Medicines Agency Approves SmPC Change to Baxter's ADVATE to Include Information on PK-Guided Dosing Study
View more recent headlines
Personalized, PK-Guided Dosing Shown to be as Effective as Standard Prophylaxis in Reducing Annual Bleeding Rate for Hemophilia A Patients
LONDON--(BUSINESS WIRE)--July 22, 2013--
Baxter International Inc. (NYSE:BAX) today announced that the European Medicines Agency has authorized an update to the Summary of Product Characteristics (SmPC) for Baxter's ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method, (in the EU, ADVATE, octocog alfa)] to include findings of the Phase IV prophylaxis study.
Company Background
Baxter International Inc. (Baxter) is a global, diversified healthcare company. Baxter, through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The Company operated in two segments: BioScience and Medication Delivery. It is engaged in the medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, clinical and medical research laboratories, and by patients at home under physician supervision. In February 2012, it acquired Synovis Life Technologies, Inc. In November 2011, it acquired Baxa Corporation. In April 2012, it purchased SIGMA International General Medical Apparatus, LLC.
Bid/Size -- / -- | Ask/Size -- / -- |
Price Open 72.83 | Previous Close 72.81 |
Day High 73.42 | Day Low 72.4099 |
52wk High/Date 74.60 / 7/23/2013 | 52wk Low/Date 56.95 / 7/26/2012 |
% off 52wk High -2.12% | % off 52wk Low 28.22% |
Beta (5 Yr) 0.6 | Market Capitalization 39.6B |
Shares Outstanding 542.0M | Volatility Avg 16.18 |
EPS(TTM) 4.02 | P/E Ratio 18.2x |
Dividend Announcement 7/23/2013 | Dividend Yield 2.68% |
Ex-Date 9/4/2013 | Date of Record 9/6/2013 |
Payable 0.49 - QRTR | Payable Date 10/1/2013 |
Last Trade as of 7/26/2013 4:00 PM ET | |
BAX Baxter International Inc vs. Peers
| Peers | |
|---|---|
BAX Baxter International Inc | 9.54% |
Boston Scientific Corporation | 91.27% |
Johnson & Johnson | 32.43% |
Abbott Laboratories | 17.36% |
BAX Baxter International Inc | 2.68% |
Boston Scientific Corporation | -- |
Johnson & Johnson | 2.84% |
Abbott Laboratories | 1.52% |
BAX Baxter International Inc | 0.29% |
Boston Scientific Corporation | 1.20% |
Johnson & Johnson | 0.28% |
Abbott Laboratories | 0.55% |